
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
This study is looking at the long term benefits and risks of taking aspirin and esomeprazole to help prevent oesophageal cancer. It is a continuation of the AspECT trial.
It is open to people who took part in the AspECT trial.
Cancer Research UK supports this study.
The AspECT trial looked at aspirin and esomeprazole to see whether it could reduce the risk of oesophageal cancer for people with Barrett’s oesophagus.
In this trial there were 4 groups. It was a . People were put into one of the following at random:
The results of the AspECT trial showed that high doses of esomeprazole by itself reduced the risk of oesophageal cancer. It also showed that the combination of high dose of esomeprazole and aspirin might be better than high dose esomeprazole by itself.
In this study the team will look at your medical records over a long period of time.
The team think the results of this study could change the national guidelines about how best to prevent Barrett’s oesophagus developing into cancer.
The aims are to find out:
Who can take part
You may be able to join this study if you took part in the AspECT trial and you agree that the study team can look at your medical records.
This is a phase 4 study. The team are looking at a maximum of 1,587 people to take part.
The study team will collect information from your medical and NHS records. This will include:
You don’t have any further treatment as part of this study.
There are no hospital visits.
There are no side effects.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Janusz Jankowski
Cancer Research UK
University College London (UCL)
This is Cancer Research UK trial number is CRUK/21/020.
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.